Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
BioElectronics Corporation: BioElectronics to Present at Upcoming RedChip and Health Tech Investment Forum on March 24th
FREDERICK, MD--(Marketwire - March 19, 2009) - BioElectronics Corp. (
"We are very excited to have been invited to present at this conference. Over the past few quarters much has changed at BioElectronics. Our customers and distributors are responding positively to the vastly improved quality represented in our new product lines," commented Andrew Whelan, CEO of BioElectronics, Corp. "Especially exciting is our new Allay menstrual pain therapy, which in the initial clinical study reduced the pain and discomfort of menstruation by up to 73%. We believe this drug-free therapy holds the potential to revolutionize the way women manage the pain and discomfort associated with menstruation. We have recently launched a larger study on menstrual pain with two prominent physicians and we expect to have initial data within 60 days. Clinical studies are also quickly coming to conclusion in areas of breast augmentation recovery and heel pain treatment, both of which are large and expanding markets. We are also continuing to expand our distribution, especially in Europe, Canada and the Middle East. This is certainly an exciting time for all of us at BioElectronics. We look forward to sharing our growth story with investors at this upcoming conference."
About BioElectronics Corporation
BioElectronics Corporation is the maker of the Allay™ Menstrual Pain Therapy, the RecoveryRx™ Therapy, ActiPatch® Therapy, and the HealFast™ Therapy for veterinary applications ([ http://www.healfasttherapy.com ]). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's Food and Drug Administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international agencies. [ http://www.bioelectronicscorp.com ]
Safe Harbor Statement
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.
